March 10, 2015
A California federal judge on Monday dismissed a proposed shareholder class action accusing experimental drug developer Vical Inc. of misleading investors about its cancer drug, describing the complaint as an attempt to punish a corporation and its officers for expressing incorrect opinions.
October 31, 2013
Vical Inc., which researches and develops biopharmaceutical products for the prevention and treatment of serious diseases, on Wednesday was hit with a putative class action in California federal court by a shareholder who says the company made false statements about the progress of cancer drug Allovectin-7.